Back to results
US 9,956,292 B2Granted
Anti-methanogenic compositions and uses thereof
AssigneesCedars-Sinai Medical Center, Synthetic Biologics, Inc.
InventorsMark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
Life of this patent
Estimating the term…
Abstract
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
Claims22
A pharmaceutical formulation, comprising at least two types of modified-release particles, each modified-release particle containing:
- about 5-20% by weight antimethanogenic statin;
- about 50-70% by weight microcrystalline cellulose;
- about 1-10% by weight copovidone;
- about 0.1-3.0% by weight silicon dioxide;
- about 0.1-3.0% by weight magnesium stearate;
- about 1-10% by weight crospovidone;
- and
- about 10-20% by weight enteric polymer,
- wherein each modified-release particle comprises about 7 mg of the antimethanogenic statin;
- wherein a first type of modified-release particle comprises a first enteric polymer that dissolves at a pH of about 5.5 and a second type of modified-release particle comprises a second enteric polymer that dissolves at a pH of about 7.0.
7 more elements
A pharmaceutical formulation, comprising:
- about 5-20% by weight of the antimethanogenic statin;
- about 30-60% by weight microcrystalline cellulose;
- about 1-10% by weight copovidone;
- about 0.1-3.0% by weight silicon dioxide;
- about 0.1-3.0% by weight magnesium stearate;
- about 1-10% by weight crospovidone;
- about 0.5-10% by weight a first enteric polymer that dissolves at a pH of about 5.5 and encapsulates a first type particle comprising the antimethanogenic statin;
- about 1-15% by weight a second enteric polymer that dissolves at a pH of about 7.0 and encapsulates a second type particle comprising the antimethanogenic statin;
- wherein each particle comprises about 7 mg of the antimethanogenic statin;
- wherein the first type particle and the second type particle are present in a ratio of about 1:2, such that the formulation has a unit dosage of about 21 mg.
7 more elements
A pharmaceutical formulation, comprising:
- about 5-20% by weight of the antimethanogenic statin;
- about 30-60% by weight microcrystalline cellulose;
- about 1-10% by weight copovidone;
- about 0.1-3.0% by weight silicon dioxide;
- about 0.1-3.0% by weight magnesium stearate;
- about 1-10% by weight crospovidone;
- about 0.5-10% by weight a first enteric polymer that dissolves at a pH of about 5.5 and encapsulates a first type particle comprising the antimethanogenic statin;
- about 1-15% by weight a second enteric polymer that dissolves at a pH of about 7.0 and encapsulates a second type particle comprising the antimethanogenic statin;
- wherein each particle comprises about 7 mg of the antimethanogenic statin;
- wherein the first type particle and the second type particle types are present in a ratio of about 1:5, such that the formulation has a unit dosage of about 42 mg.
7 more elements
Dependencies are inferred from the claim text.